Search results
AbbVie (NYSE:ABBV) Stock Rating Reaffirmed by Cantor Fitzgerald
ETF DAILY NEWS· 12 hours agoAbbVie (NYSE:ABBV – Get Free Report)‘s stock had its “overweight” rating reissued by Cantor Fitzgerald in a note issued to investors on Thursday, Benzinga reports. Cantor ...
AbbVie Inc. (NYSE:ABBV) Shares Sold by Stableford Capital II LLC
ETF DAILY NEWS· 24 hours agoStableford Capital II LLC decreased its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 6.2% in the 1st quarter, Holdings Channel reports. The firm owned 5,038 shares of ...
AbbVie names Roxanne Austin as new lead independent director By Investing.com
Investing.com· 2 days agoAustin will be taking over from Glenn F. Tilton, who will continue his tenure on the board as an...
Safeguard Financial LLC Takes $235,000 Position in AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 23 hours agoSafeguard Financial LLC acquired a new stake in AbbVie Inc. (NYSE:ABBV – Free Report) in the first quarter, according to the company in its most recent Form 13F filing with ...
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
Zacks via Yahoo Finance· 1 day agoFDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use...
Pensionfund Sabic Sells 3,100 Shares of AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 2 days agoPensionfund Sabic lowered its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 15.7% during the first quarter, according to the company in its most recent Form 13F filing ...
CCM Investment Advisers LLC Trims Stock Holdings in AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 5 days agoCCM Investment Advisers LLC trimmed its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 0.1% during the 4th quarter, according to the company in its most recent Form ...
AbbVie (NYSE:ABBV) Given New $190.00 Price Target at Piper Sandler
ETF DAILY NEWS· 4 days agoAbbVie (NYSE:ABBV – Get Free Report) had its price objective boosted by research analysts at Piper Sandler from $185.00 to $190.00 in a research note issued on Tuesday, Benzinga ...
AbbVie (ABBV) Exceeds Market Returns: Some Facts to Consider
Zacks via Yahoo Finance· 4 days agoThe latest trading session saw AbbVie (ABBV) ending at $171.36, denoting a +0.99% adjustment from...
AbbVie stock price forecast: $200 on the cards? | Invezz
Invezz· 2 days agoOn June 20, 2024, AbbVie Inc. (NYSE:ABBV) announced that it has received FDA approval for expanding the use of its interleukin-23 (IL-23) inhibitor, Skyrizi, to treat adults ...